Gwo Xi Stem Cell Applied Technology Co. , Ltd
6704
Rank in Stocks
#21597
Gwo Xi Stem Cell Applied Technology Co., Ltd. is dedicated to advancing stem... Gwo Xi Stem Cell Applied Technology Co., Ltd. is dedicated to advancing stem cell-based therapies, addressing critical unmet medical needs in patient care. Its product pipeline currently features two pioneering autologous adipose-derived stem cell treatments: GXHPC1, which is in Phase II clinical trials for liver cirrhosis, and GXNPC1, also undergoing Phase II testing, designed for the management of chronic stroke. Further expanding its therapeutic portfolio, the company is advancing GXCPC1, an allogeneic adipose-derived stem cell therapy currently in combined Phase I/II clinical trials for osteoarthritis, alongside GXIPC1, another allogeneic fat-derived stem cell treatment in early-stage Phase I trials for diabetes. Established in 2011, the company maintains its headquarters in Zhubei, Taiwan.
Share Price
$0.61578607
Last synced: 2026-11-10
Market Cap
$65.24M
Change (1 day)
0.25%
Change (1 year)
-27.57%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)
Category
Healthcare
EPS for Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)
EPS as of June 2026 TTM: $-0.03
According to Gwo Xi Stem Cell Applied Technology Co. , Ltd's latest financial reports, its current EPS (TTM) is $-0.03. At the end of 2025 the company had an EPS of $-0.03, equal to its 2024 EPS of $-0.03.
EPS history for Gwo Xi Stem Cell Applied Technology Co. , Ltd from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.03 | 6.00% |
| 2025 | $-0.03 | 1.13% |
| 2024 | $-0.03 | -16.93% |
| 2023 | $-0.03 | -25.29% |
| 2022 | $-0.04 | -6.77% |
| 2021 | $-0.05 | 33.92% |
| 2020 | $-0.03 | 1.18% |
| 2019 | $-0.03 | -39.86% |
| 2018 | $-0.06 | 36.74% |
| 2017 | $-0.04 | 11.08% |
| 2016 | $-0.04 | -11.69% |
| 2015 | $-0.04 | -44.13% |
| 2013 | $-0.08 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -49,345.28% |
US
|
|
| $-7.07 | 22,132.70% |
US
|
|
| $-5.29 | 16,535.22% |
AU
|
|
| $12.88 | -40,603.46% |
BE
|
|
| $21.56 | -67,898.74% |
NL
|
Questions about Gwo Xi Stem Cell Applied Technology Co. , Ltd's earnings per share (EPS)
What is Gwo Xi Stem Cell Applied Technology Co. , Ltd's earnings per share (EPS)?
Gwo Xi Stem Cell Applied Technology Co. , Ltd's earnings per share (EPS) over the last twelve months is $-0.03, as of Jun 2026.
What was Gwo Xi Stem Cell Applied Technology Co. , Ltd's earnings per share (EPS) in 2025?
In 2025, Gwo Xi Stem Cell Applied Technology Co. , Ltd's earnings per share (EPS) was $-0.03, compared with $-0.03 in 2024.
How has Gwo Xi Stem Cell Applied Technology Co. , Ltd's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Gwo Xi Stem Cell Applied Technology Co. , Ltd's earnings per share (EPS) was highest in 2025 ($-0.03) and lowest in 2021 ($-0.05).
How does Gwo Xi Stem Cell Applied Technology Co. , Ltd's earnings per share (EPS) compare with similar companies?
Gwo Xi Stem Cell Applied Technology Co. , Ltd's earnings per share (EPS) ($-0.03) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.